ProCE Banner Activity

Emerging Therapies in the Treatment of Patients With Higher Risk MDS in Frontline and Post-HMA Failure Settings

Slideset Download

Download these slides from a live symposium for expert guidance on managing patients with either newly diagnosed or HMA-refractory higher risk MDS.

Released: December 09, 2022

Expiration: December 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bristol Myers Squibb

Geron

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Amer Zeidan, MBBS, MHS

Professor of Medicine
Chief, Division of Hematologic Malignancies​
Yale Comprehensive Cancer Center and Smilow Cancer Hospital​
New Haven, Connecticut

Amer M. Zeidan, MBBS, MHS: researcher: AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka, Pfizer, Takeda, Trovagene; consultant: Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Cardinal Health, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, Tyme.